Scipher Medicine: Funding, Investors & Team (Oct 2026)
At Scipher Medicine, we are committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. We have built a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, we can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For our first commercial product, we have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. We also used a different one for the ACO Payer Summit, I’ve provided that as well: Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Scipher Medicine has raised $192M across 2 funding rounds on record, the most recent a Series D of $110M announced in Feb 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Scipher Medicine Company Profile and Key Stats
Latest funding round on record: Feb 2022.
Scipher Medicine Funding Rounds
Scipher Medicine raised $82.0M in a Series C announced in Mar 2021.
11 months later, a Series D of $110M was announced in Feb 2022.
Scipher Medicine Founders and Leadership Team
Contact details for the Scipher Medicine team: 1 of 1 has an email address on file.
Start 14-day free trial →Scipher Medicine Funding Compared to Other Biotechnology Startups
Scipher Medicine's latest round of $110M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Scipher Medicine in Biotechnology and Waltham
Companies Similar to Scipher Medicine
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Scipher Medicine Funding FAQs
What does Scipher Medicine do?
At Scipher Medicine, we are committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. We have built a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, we can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For our first commercial product, we have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. We also used a different one for the ACO Payer Summit, I’ve provided that as well: Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
How much funding has Scipher Medicine raised?
Scipher Medicine has raised $192M across 2 rounds on record. The most recent is a Series D of $110M announced in Feb 2022.
When did Scipher Medicine last raise funding?
Scipher Medicine's most recent funding round on record is a Series D of $110M, announced in Feb 2022.
Who is the CEO of Scipher Medicine?
Alif Saleh is listed as CEO at Scipher Medicine.
Where is Scipher Medicine headquartered?
Scipher Medicine is based in Waltham, Massachusetts, United States.
How many employees does Scipher Medicine have?
Scipher Medicine is in the 101-250 employee band.
How does Scipher Medicine's funding compare to other Biotechnology startups?
Scipher Medicine's latest round of $110M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Scipher Medicine Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Scipher Medicine is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.